Research Topics
Species | J M GalloSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor modelsShining Wang
Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
Mol Cancer Ther 7:407-17. 2008..The novel concept of PK/PD equivalent dosing regimens could be applied in drug development and to delineate PG differences in drug activity...
Population pharmacokinetic model for topotecan derived from phase I clinical trialsJ M Gallo
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 18:2459-67. 2000..To characterize the pharmacokinetics of topotecan in a population model that would identify patient variables or covariates that appreciably impacted on its disposition...- The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in miceJames M Gallo
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Res 63:5114-7. 2003..It is concluded that even in the neovasculature of brain tumors, Pgp has the facility to limit drug penetration, although somewhat less so than in normal brain... - Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470J Ma
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Res 61:5491-8. 2001..It is increasingly important to understand the pharmacokinetic and pharmacodynamic behavior of each class of drug so that optimal dosing regimens can be designed... - Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignanciesG R Hudes
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 6:3071-80. 2000..o. three times daily is well tolerated on a 14-day on/14-day off dosing schedule. Inhibition of p21ras function in humans is not likely to occur after POH administration at safe doses of the present oral formulation... - Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapyR J Schilder
Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 19:1183-94. 2001..This approach remains experimental and should be used only in the context of a clinical trial... - Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft modelP Guo
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 48:169-76. 2001..This type of target selectivity would allow higher tumor concentrations to be achieved in conjunction with lower drug concentrations in normal or non-target tissues... - Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancerWeijing Sun
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Clin Cancer Res 8:3100-4. 2002..Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule... - Phase I and pharmacokinetic study of irinotecan in combination with raltitrexedNancy L Lewis
Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 50:257-65. 2002..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination... - Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted miceGary D Kruh
Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Metastasis Rev 26:5-14. 2007..This review will discuss insights into the physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 afforded by investigations of these new mouse models... 
Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometryPing Guo
School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
J Pharm Biomed Anal 43:1789-95. 2007..The method has the advantages of low sample volume, rapid clean-up, and the simultaneous measurement of MTX and 7-OH MTX in plasma and brain tissues allowing detailed PK studies to be completed in individual mice...- Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimensQingyu Zhou
Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
J Pharmacol Exp Ther 321:265-75. 2007..In conclusion, several PK/PD factors contributing to the antitumor activity of the MD TMZ therapy have been identified and form a foundation for further investigations of low-dose TMZ regimens... - Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain dispositionQingyu Zhou
Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
Clin Cancer Res 13:4271-9. 2007..Our goal was to show how the latter could be achieved for temozolomide, an agent used in the treatment of brain tumors, using an orthotopic brain tumor model in rats... - Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damageMartin G Belinsky
Medical Science Division, Department of Pathology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer Res 67:262-8. 2007..This is the first demonstration that an ATP-binding cassette transporter can affect in vivo tissue sensitivity towards this class of agents... - In vivo microdialysis for PK and PD studies of anticancer drugsQingyu Zhou
Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
AAPS J 7:E659-67. 2005.... - Pharmacokinetic model-predicted anticancer drug concentrations in human tumorsJames M Gallo
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19140, USA
Clin Cancer Res 10:8048-58. 2004..It is believed that this modeling strategy can be used as an aid in the drug development process by providing key insights into drug disposition in tumors and by offering a foundation to optimize drug regimen design... - Population pharmacokinetics of cisplatin in adult cancer patientsFelix E de Jongh
Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands
Cancer Chemother Pharmacol 54:105-12. 2004..To characterize the pharmacokinetics of the anticancer agent cisplatin, and explore the influence of patient covariates and interoccasion variability on drug disposition... - Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin
Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 6:65-74. 2004..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials... - Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometryPing Guo
Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
J Chromatogr B Analyt Technol Biomed Life Sci 798:79-86. 2003..054 to 1.96 microg/ml in brain homogenates. A sensitive and specific assay for paclitaxel has been developed that has the advantages of using small sample sizes, and a single extraction step without solvent evaporation... - Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumorsGiuseppe Trapani
Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
Bioconjug Chem 14:830-9. 2003..A plausible degradation pathway accounting for the available experimental data is presented... - Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell supportMeiyu Shen
Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 50:243-50. 2002..In both cases, the models performed well when analyzed in the context of the retrospective and bootstrap analyses. Prospective studies in ovarian cancer patients should be conducted to further tailor the current models... - Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistanceJianguo Ma
Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
Biochem Pharmacol 63:1219-28. 2002.... - Cells designed to deliver anticancer drugs by apoptosisJianguo Ma
Department of Pharmacology Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Res 62:1382-7. 2002..Apoptosis-induced drug delivery offers a new avenue for targeted drug delivery research that uses biological control mechanisms...